1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39641
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZamboni W.C.en
dc.contributor.authorGangadhar T.C.en
dc.contributor.authorPiha-Paul S.A.en
dc.contributor.authorMurphy C.en
dc.contributor.authorSenderowicz A.en
dc.contributor.authorWang H.en
dc.contributor.authorMarkman B.en
dc.contributor.authorde Souza P.en
dc.contributor.authorDees E.C.en
dc.date.accessioned2021-05-14T13:32:08Zen
dc.date.available2021-05-14T13:32:08Zen
dc.date.copyright2016en
dc.date.created20200326en
dc.date.issued2020-03-26en
dc.identifier.citationAnnals of Oncology. 27 (Supplement 6) (pp vi134), 2016. Date of Publication: 1 October 2016.en
dc.identifier.issn0923-7534en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/39641en
dc.languageenen
dc.publisherElsevier Ltden
dc.relation.ispartofAnnals of Oncologyen
dc.subject.meshdrug blood level-
dc.subject.meshdrug dose escalation-
dc.subject.meshdrug safety-
dc.subject.meshdrug tolerability-
dc.subject.meshmaximum tolerated dose-
dc.subject.meshphase 1-
dc.subject.meshphase 2-
dc.subject.meshsolid malignant neoplasm-
dc.subject.meshantineoplastic agent/ct-
dc.subject.meshantineoplastic agent-
dc.subject.meshcyclodextrin-
dc.subject.meshdocetaxel-
dc.subject.meshmacrogol-
dc.subject.meshnanop-
dc.subject.mesh|antineoplastic activity-
dc.subject.meshadvanced cancer-
dc.titleA dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies.en
dc.typeArticleen
dc.identifier.affiliationOncology-
dc.type.studyortrialClinical trial-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/annonc/mdw368.56-
dc.publisher.placeUnited Kingdomen
dc.identifier.source2004422900en
dc.identifier.institution(Wang) Research, Cerulean Pharma, Inc., Waltham, MA, United States (Markman) Monash Cancer Centre, Monash Health, Melbourne, Australia (de Souza) Medical Oncology, Western Sydney University School of Medicine, Sydney, Australia (Dees) Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States (Gangadhar) Hematology-Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, United States (Piha-Paul) Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States (Zamboni) UNC Lineberger Comprehensive Cancer Center, UNC Eshelman School of Pharmacy, Carolina Center for Cancer Nanotechnology Excellence, Chapel Hill, NC, United States (Murphy, Senderowicz) Clinical Operations, Cerulean Pharma, Inc., Waltham, MA, United Statesen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:Articles
Show simple item record

Page view(s)

20
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.